This analysis examines the historical and forecast performance for Menarini in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Scope
Highlights of this title
Key reasons to purchase this title
- Benchmark Menarinis performance against key rivals in the ethical pharmaceutical sector
- See how Menarini will achieve relatively low growth as the small gains made by some products are counteracted by the small losses felt by others
- Learn how despite the launch of its first major internally discovered product, amediplase, the company will remain heavily reliant on externalization
